Poolbeg Pharma PLC operates as a clinical stage infectious disease pharmaceutical company in the United Kingdom. Its products include POLB 001, a Phase-II ready p38 MAP Kinase inhibitor that reduces harmful inflammation in patients with severe forms of influenza; PredictViral Biomarker Platform, a tool for predicting severe diseases; and vaccine discovery platform, which are techniques used in human challenge models to identify vaccine candidates that drive preferential T-Cell immune responses. The company was formerly known as Orph Pharma Limited and changed its name to Poolbeg Pharma PLC in June 2021. Poolbeg Pharma PLC was incorporated in 2021 and is headquartered in London, the United Kingdom. The company trades on AIM exchange marketplace. The company headquarter is located in London, United Kingdom. The company was established in the 2021. The company's ISIN is GB00BKPG7Z60.
TickerPOLB
Long NamePoolbeg Pharma PLC
Short NamePoolbeg Pharma PLC
SectorHealthcare
SubsectorBiotechnology
Subsector 2
CurrencyGBX
ISINGB00BKPG7Z60